• N Kerckhove, B Pereira, S Soriot-Thomas, H Alchaar, R Deleens, V S Hieng, E Serra, M Lanteri-Minet, P Arcagni, P Picard, D Lefebvre-Kuntz, C Maindet, G Mick, L Balp, C Lucas, C Creach, M Letellier, V Martinez, M Navez, D Delbrouck, E Kuhn, E Piquet, E Bozzolo, C Brosse, B Lietar, F Marcaillou, A Hamdani, N Leroux-Bromberg, Y Perier, P Vergne-Salle, C Gov, N Delage, D Gillet, S Romettino, D Richard, C Mallet, L Bernard, C Lambert, C Dubray, C Duale, and A Eschalier.
• Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de l'Innovation, CETD, CIC, CNRS, SIGMA Clermont, ICCF, Service de Pharmacie, Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM - NEURO-DOL, Clermont-Ferrand, France.
• Eur J Pain. 2018 Aug 1; 22 (7): 1321-1330.

BackgroundT-type calcium channels have been shown to play an important role in the initiation and maintenance of neuropathic pain and represent a promising therapeutic target for new analgesic treatments. Ethosuximide (ETX), an anticonvulsant and a T-type channel blocker has shown analgesic effect in several chronic pain models but has not yet been evaluated in patients with neuropathic pain.MethodsThis proof-of-concept, multicentre, double-blind, controlled and randomized trial compared the efficacy and safety of ETX (given as add-on therapy) to an inactive control (IC) in 114 patients with non-diabetic peripheral neuropathic pain. After a 7-day run-in period, eligible patients aged over 18 years were randomly assigned (1:1) to ETX or IC for 6 weeks. The primary outcome was the difference between groups in the pain intensity (% of change from the baseline to end of treatment) assessed in the intention-to-treat population. This study is registered with EudraCT (2013-004801-26) and ClinicalTrials.gov (NCT02100046).ResultsThe study was stopped during the interim analysis due to the high number of adverse events in the active treatment group. ETX failed to reduce total pain and showed a poor tolerance in comparison to IC. In the per-protocol analysis, ETX significantly reduced pain intensity by 15.6% (95% CI -25.8; -5.4) from baseline compared to IC (-7.8%, 95% CI -14.3; -1.3; p = 0.033), but this result must be interpreted with caution because of a small subgroup of patients.ConclusionEthosuximide did not reduce the severity of neuropathic pain and induces, at the doses used, many adverse events.SignificanceThis article shows that ETX is not effective to treat neuropathic pain. Nevertheless, per-protocol analysis suggests a possible analgesic effect of ETX. Thus, our work adds significant knowledge to preclinical and clinical data on the benefits of T-type calcium channel inhibition for the treatment of neuropathic pain.© 2018 European Pain Federation - EFIC®.

20 keywords...

hide…